PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
26 abril 2024
ASCO 2024 . Overall Survival Of ADEBRELIMAB Plus Chemotherapy And Sequential Thoracic Re Radiotherapy As First-Line Treatment For EXTENSIVE-STAGE Small Cell Lung Cancer .
